Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00352339
Status:
UNKNOWN
Last Update Posted:
2009-08-06
First Post:
2006-07-13
Brief Title:
The New Strategy for Pharmacological Treatment in People With Schizophrenia
Sponsor:
Inje University
Organization:
Inje University
Study Overview
Official Title:
Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia
Status:
UNKNOWN
Status Verified Date:
2009-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia
Detailed Description:
It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia However this classical strategy produces long term adverse events of drug such as TD osteoporosis and some metabolic syndrome To overcome these adverse events new strategy for pharmacological treatment is needed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None